Wall Street Zen Downgrades Taysha Gene Therapies (NASDAQ:TSHA) to Sell

Taysha Gene Therapies (NASDAQ:TSHA) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other equities analysts have also commented on the stock. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. UBS Group set a $11.00 target price on Taysha Gene Therapies in a research report on Thursday, December 4th. The Goldman Sachs Group set a $11.00 price target on Taysha Gene Therapies in a report on Thursday, December 4th. JMP Securities set a $8.00 price objective on Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research report on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.42.

Taysha Gene Therapies Trading Down 4.5%

Shares of TSHA opened at $5.25 on Friday. The business’s 50-day moving average price is $4.91 and its 200 day moving average price is $3.79. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $1.44 billion, a P/E ratio of -15.91 and a beta of 1.02. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insiders Place Their Bets

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 260,047 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97. Following the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at $4,539,039.89. This represents a 20.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.78% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Several large investors have recently made changes to their positions in TSHA. ST Germain D J Co. Inc. increased its holdings in Taysha Gene Therapies by 81.8% in the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares during the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Taysha Gene Therapies in the third quarter worth approximately $40,000. Marex Group plc acquired a new position in shares of Taysha Gene Therapies during the 2nd quarter worth $29,000. E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at $31,000. Finally, Allegheny Financial Group bought a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at $49,000. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.